Physician profile
Paul Daniel Kirkpatrick
NPI 1225520067
$519.46
in general payments reported to CMS, 2019-2025
10 companies · $98.18 in 2025
The $98.18 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.33 · 2022: $54.70 · 2023: $142 · 2024: $188 · 2025: $98.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $231.61 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $70.21 | 2025 | Winrevair |
| Insmed, INC. | $36.33 | 2021 | |
| Shionogi INC | $34.51 | 2023 | Fetroja |
| La Jolla Pharmaceutical Company | $30.48 | 2023 | Giapreza |
| Actelion Pharmaceuticals US, INC. | $29.82 | 2022 | |
| Noctrix Health, INC. | $27.97 | 2025 | Nidra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.66 | 2023 | |
| Phadia US INC. | $17.92 | 2023 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $13.95 | 2024 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kirkpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.